Form 4: Apyx Medical Director Receives Stock Option Grant

Director Lawrence Waldman was granted 50,000 stock options in Apyx Medical Corporation as part of an equity incentive.

Summary

• Director Lawrence Waldman received a grant of 50,000 stock options for Apyx Medical Corporation (APYX).
• The options have an exercise price of $4.65 per share.
• The grant date is June 11, 2026, with an expiration date of June 11, 2036.
• The options vest ratably over a 12-month period, becoming fully exercisable on the first anniversary of the grant.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in potential future dilution for existing shareholders upon exercise of the options.

Risks

• Market price volatility could impact the value of the options and the incentive alignment.

Future Outlook

The options vest over a one-year period, indicating a long-term retention and performance incentive for the director.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice to ensure board members maintain a vested interest in the company's long-term performance.

Comparison to Industry Standards

• The 12-month vesting schedule is consistent with standard equity compensation practices for board members in the medical device sector.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution if these options are exercised in the future.

Next Steps

• Vesting of options over the next 12 months.
• Potential exercise of options by the director after the vesting period.

Key Dates

Keywords

Apyx Medical, APYX, Director Compensation, Stock Options, Insider Transaction, Form 4